Golden has been acquired by ComplyAdvantage.Read about it here ⟶

‌

US Patent 7667039 1,3-dihydro-imidazo [4,5-C] quinolin-2-ones as lipid kinase inhibitors

Patent 7667039 was granted and assigned to Novartis on February, 2010 by the United States Patent and Trademark Office.

Overview Structured Data Issues Contributors Activity

Is a

Patent

Patent attributes

Current Assignee

Novartis

Patent Jurisdiction

United States Patent and Trademark Office

Patent Number

7667039

Patent Inventor Names

Carlos Garcia-Echeverria0

Frédéric Stauffer0

Pascal Furet0

Date of Patent

February 23, 2010

Patent Application Number

11913788

Date Filed

May 18, 2006

Patent Citations Received

‌

US Patent 12091411 IRAK degraders and uses thereof

‌

US Patent 11746120 Stat degraders and uses thereof

‌

US Patent 11779578 IRAK degraders and uses thereof

‌

US Patent 11932635 CRBN ligands and uses thereof

‌

US Patent 11932624 MDM2 degraders and uses thereof

‌

US Patent 12006329 Protein degraders and uses thereof

‌

US Patent 12077555 STAT degraders and uses thereof

‌

US Patent 11679109 SMARCA degraders and uses thereof

...

Patent Primary Examiner

Emily Bernhardt

Patent abstract

The invention relates to novel organic compounds of formula (I)

Timeline

No Timeline data yet.

Further Resources

Title

Author

Link

Type

Date

No Further Resources data yet.

References

Find more entities like US Patent 7667039 1,3-dihydro-imidazo [4,5-C] quinolin-2-ones as lipid kinase inhibitors

Use the Golden Query Tool to find similar entities by any field in the Knowledge Graph, including industry, location, and more.

Open Query Tool

Access by API